HC Wainwright Has Optimistic Outlook of DVAX FY2026 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX) – Investment analysts at HC Wainwright increased their FY2026 earnings per share estimates for Dynavax Technologies in a research note issued on Friday, February 21st. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will post earnings per share of $0.54 for the year, up from their previous estimate of $0.45. HC Wainwright has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Dynavax Technologies’ FY2027 earnings at $0.69 EPS.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. The company had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%.

DVAX has been the subject of a number of other reports. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday. The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their price objective for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th. Finally, StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th.

Dynavax Technologies Price Performance

Shares of DVAX stock opened at $13.33 on Monday. The stock has a 50 day moving average of $12.82 and a 200 day moving average of $12.04. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The stock has a market cap of $1.75 billion, a P/E ratio of 74.06 and a beta of 1.32. Dynavax Technologies has a twelve month low of $9.74 and a twelve month high of $14.05.

Institutional Trading of Dynavax Technologies

Institutional investors and hedge funds have recently made changes to their positions in the business. US Bancorp DE boosted its stake in shares of Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 1,169 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 2,034 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Dynavax Technologies in the fourth quarter worth approximately $35,000. Finally, Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies in the third quarter worth approximately $45,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.